{
    "name": "nirmatrelvir/ritonavir",
    "comment": "Investigational",
    "other_names": [
        "Paxlovid"
    ],
    "classes": [
        "Antivirals",
        "SARS-CoV-2"
    ],
    "source": "https://reference.medscape.com/drug/paxlovid-nirmatrelvir-ritonavir-4000259",
    "pregnancy": {
        "common": [
            "Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19"
        ],
        "specific": [
            {
                "type": "Nirmatrelvir",
                "description": [
                    "Human data are unavailable on use of nirmatrelvir during pregnancy to evaluate for drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes"
                ]
            },
            {
                "type": "Ritonavir",
                "description": [
                    "Observational studies on ritonavir use in pregnant females have not identified an increase in the risk of major birth defects",
                    "Studies with ritonavir are insufficient to identify a drug-associated risk of miscarriage"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "There are maternal and fetal risks (eg, preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, fetal death) associated with untreated COVID-19 in pregnancy"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Use of ritonavir may reduce efficacy of combined hormonal contraceptives",
                    "Advise patients using combined hormonal contraceptives to use an effective alternative contraceptive method or an additional barrier method of contraception"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Nirmatrelvir: Reduced fetal body weights following oral administration to pregnant rabbits were observed at systemic exposures (AUC) ~10x higher than clinical exposure at the authorized human dose",
                    "Ritonavir: No evidence of teratogenicity for rats and rabbits at systemic exposures of ~4x higher than authorized human dose exposure"
                ]
            },
            {
                "type": "Nirmatrelvir",
                "description": [
                    "Human data are unavailable on use of nirmatrelvir during pregnancy to evaluate for drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes"
                ]
            },
            {
                "type": "Ritonavir",
                "description": [
                    "Observational studies on ritonavir use in pregnant females have not identified an increase in the risk of major birth defects",
                    "Studies with ritonavir are insufficient to identify a drug-associated risk of miscarriage"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "History of clinically significant hypersensitivity reactions (eg, toxic epidermal necrolysis [TEN], Stevens-Johnson syndrome [SJS]) to nirmatrelvir or ritonavir"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions reported including urticaria, angioedema, dyspnea, mild skin eruptions, and pruritus; cases of anaphylaxis; TEN, and SJS reported with ritonavir; if significant hypersensitivity reaction or anaphylaxis occurs, immediately discontinue and initiate appropriate medications and/or supportive care ",
                "Hepatic transaminase elevations, clinical hepatitis, and jaundice reported with ritonavir; caution when administering to patients with preexisting liver diseases, liver enzyme abnormalities, or hepatitis",
                "Because nirmatrelvir is coadministered with ritonavir, possible risk of developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection "
            ],
            "specific": [
                {
                    "type": "COVID-19 rebound",
                    "description": [
                        "May 24, 2022: CDC has issued a ",
                        "health advisory",
                        " regarding potential for recurrence of COVID-19 or “viral RNA rebound” after case reports documented persons treated with nirmatrelvir/ritonavir and having recovered can experience recurrent illness ",
                        "COVID-19 rebound is characterized by reoccurrence of symptoms or a new positive viral test after having testing negative ",
                        "Currently, there is no evidence that additional treatment is needed for COVID-19 rebound and patient monitoring continues to be the most appropriate management of symptom reoccurrence ",
                        "Persons with COVID-19 rebound should ",
                        "Re-isolate for at least 5 days",
                        "Per CDC guidance, they can end their re-isolation period after 5 full days if fever has resolved for 24 hr (without use of antipyretics) and symptoms are improving",
                        "The patient should wear a mask for a total of 10 days after rebound symptoms started ",
                        "Consider clinical evaluation of patients who have COVID-19 rebound and symptoms that persist or worsen ",
                        "Healthcare workers are encouraged to report cases of COVID-19 rebound to after Paxlovid treatment using ",
                        "Pfizer Safety Reporting",
                        " or ",
                        "FDA MedWatch"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Potential for nirmatrelvir and ritonavir to affect other drugs",
                        "Nirmatrelvir and ritonavir is an inhibitor of CYP3A and may increase drugs primarily metabolized by CYP3A",
                        "Coadministration with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated",
                        "Potential for other drugs to affect nirmatrelvir and ritonavir",
                        "Nirmatrelvir and ritonavir are CYP3A substrates; therefore, drugs that induce CYP3A may decrease nirmatrelvir and ritonavir plasma concentrations and reduce therapeutic effect"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "amiodarone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "clozapine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "colchicine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dronedarone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eletriptan",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of eletriptan within at least 72 hours of nirmatrelvir/ritonavir is contraindicated owing to potential for serious adverse reactions including cardiovascular and cerebrovascular events."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eplerenone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. May increase risk of hyperkalemia associated with eplerenone. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ergotamine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "finerenone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. May increase risk of hyperkalemia, hypotension, and hyponatremia associated with finerenone. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "flecainide",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of flecainide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "flibanserin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. May increase risk of hypotension, syncope, and CNS depression associated with flibanserin."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ivabradine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of ivabradine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. May increase risk of bradycardia or conduction disturbances associated with ivabradine. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lomitapide",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of lomitapide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. May increase risk of hepatotoxicity and GI effects associated with lomitapide."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lovastatin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. Discontinue lovastatin at least 12 hr before initiating nirmatrelvir/ritonavir , during the 5 days of treatment, and for 5 days after completing. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "lumacaftor/ivacaftor will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lurasidone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of lurasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mavacamten",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "meperidine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of meperidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "methylergonovine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of methylergonovine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "midazolam",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with oral midazolam. If IV midazolam required, reduce midazolam dose and administer in setting that ensures close monitoring and appropriate medical management if respiratory depression occurs."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "naloxegol",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of naloxegol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. Potential for opioid withdrawal symptoms. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pimozide",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "piroxicam",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of piroxicam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "propafenone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of propafenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "quinidine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ranolazine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sildenafil",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration contraindicated if sildenafil used for pulmonary arterical hypertension. Reduce sildenafil dose if used for erectile dysfunction."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "silodosin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. May increase risk of postural hypotension associated with silodosin. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "simvastatin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. Discontinue simvastatin at least 12 hr before initiating nirmatrelvir/ritonavir, during the 5 days of treatment, and for 5 days after completing."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tolvaptan",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. May increase risk of dehydration, hypovolemia, and hyperkalemia associated with tolvaptan."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "triazolam",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ubrogepant",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of ubrogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "voclosporin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of voclosporin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. May increase risk of acute and/or chronic nephrotoxicity associated with voclosporin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adagrasib",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of adagrasib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of adagrasib, a CYP3A4 substrate, with strong CYP3A4 inhibitors until adagrasib concentrations have reached steady-state (after ~8 days). If steady state is not reached, concomitant use of strong CYP3A4 inhibitors will increase adagrasib concentrations and risk of its toxicities"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aliskiren",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of aliskiren by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Aliskiren product labeling recommends avoiding concomitant use with CYP3A4 and P-gp inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apixaban",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of apixaban by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Apixaban is also substrate of P-gp; if concomitant administration necessary, adjust and hold dose as clinically necessary; may adjust apixaban dosage according to risk, indication and current dose; for treatment of atrial fibrillation with standard apixaban dose (eg, 5 mg twice daily), reduce apixaban to 2.5 mg twice daily; for treatment of atrial fibrillation with low dose apixaban (eg, 2.5 mg twice daily), continue low dose on case-by-case basis"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "avanafil",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of avanafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Safe and effective avanafil dosage regimen has not been established for coadministration with strong CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bosentan",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of bosentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of nirmatrelvir/ritonavir for 5 days may result in significant increases bosentan trough concentrations. Discontinue bosentan at least 36 hr before initiating nirmatrelvir/ritonavir. May resume bosentan 10 days after initiating nirmatrelvir/ritonavir. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "nirmatrelvir/ritonavir will decrease the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Clopidogrel is a prodrug and is converted to its active metabolite via CYPs 3A4, 2B6, 2C19 and 1A2. Coadministration of clopidogrel and ritonavir-boosted HIV protease inhibitors has been evaluated in clinical studies and showed that ritonavir decreased the AUC and Cmax of clopidogrel?s active metabolite. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, monitor cyclosporine serum concentration and temporarily decrease dose or alter dose frequency. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dofetilide",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of dofetilide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration not studied. Dofetilide metabolized to a small degree by CYP3A4. Nirmatrelvir/ritonavir could potentially increase dofetilide exposure. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elacestrant",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of elacestrant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elbasvir/grazoprevir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of elbasvir/grazoprevir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Increased grazoprevir concentrations can result in ALT elevations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "encorafenib",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of encorafenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration owing to potential risk of serious adverse events (eg, QT interval prolongation)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "everolimus",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "futibatinib",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of futibatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of futibatinib with drugs that are dual P-gp and strong CYP3A inhibitors may increase incidence/severity of futibatinib toxicities."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of glecaprevir/pibrentasvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Glecaprevir/pibrentasvir serum concentrations may be increased owing to P-gp, BCRP and OATP1B inhibition by ritonavir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of ibrutinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of ivosidenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration owing to potential risk of serious adverse events (eg, QT interval prolongation)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of leniolisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "neratinib",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of neratinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nilotinib",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of nilotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid with strong CYP3A4 inhibitors. If unable to avoid, reduce nilotinib dose. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omaveloxolone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of omaveloxolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unavoidable, reduce omaveloxolone dose to 50 mg/day. Closely monitor and discontinue if adverse effects emerge."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rimegepant",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of rimegepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of rivaroxaban by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid rivaroxaban with strong CYP3A4/P-gp inhibitors owing to increased bleeding risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "salmeterol",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of salmeterol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration may increase risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirolimus",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sparsentan",
            "description": {
                "common": "nirmatrelvir/ritonavir, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "suvorexant",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of suvorexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, decrease tacrolimus dose by one-third. Strong CYP3A inhibitors may increase tacrolimus whole blood trough concentrations and increase risk of serious adverse reactions (eg, neurotoxicity, QT prolongation). A rapid, sharp rise in tacrolimus levels may occur early, despite an immediate reduction of tacrolimus dose. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tadalafil",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration if tadalafil used for pulmonary arterial hpertension. Reduce tadalafil dose if used for erectile dysfunction. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tamsulosin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of tamsulosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Tamsulosin metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6. Pause tamsulosin and restart 3 days after completing nirmatrelvir/ritonavir given that CYP3A4 inhibition takes several days to resolve. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ticagrelor",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of ticagrelor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. As an alternant antiiplatelet agent, prasugrel can be used with nirmatrelvir/ritonavir unless the patient has a clinical condition which contraindicates its use in which case an alternative antiplatelet agent should be considered."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "venetoclax",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of venetoclax by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vorapaxar",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of vorapaxar by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voriconazole",
            "description": {
                "common": "nirmatrelvir/ritonavir will decrease the level or effect of voriconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of voriconazole and low-dose ritonavir (ie, 100 mg q12hr) owing to induction of CYP3A4 and CYP2C19 isoenzymes by ritonavir.  "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abemaciclib",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of abemaciclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce abemaciclib dose if coadministered with strong or moderate CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alprazolam",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider lowering alprazolam dosing when coadministered with nirmatrelvir/ritonavir"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amlodipine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce amlodipine dose by 50% during coadministration and for 3 more days after the last nirmatrelvir/ritonavir dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased nirmatrelvir/ritonavir or protease inhibitor adverse events with concomitant use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider temporary discontinuation of atorvastatin during treatment with nirmatrelvir/ritonavir."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bedaquiline",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of bedaquiline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for bedaquiline adverse effects (eg, QT prolongation). "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betamethasone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of betamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase certain systemic corticosteroid concentrations. Increased risk for Cushing syndrome and adrenal suppression. Consider alternant corticosteroids, including beclomethasone and prednisolone)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bictegravir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of bictegravir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase bictegravir systemic exposures."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "budesonide",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of budesonide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase certain systemic corticosteroid concentrations. Increased risk for Cushing syndrome and adrenal suppression. Consider alternant corticosteroids, including beclomethasone and prednisolone)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupropion",
            "description": {
                "common": "nirmatrelvir/ritonavir will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Bupropion is extensively metabolized by CYP2B6 to active metabolite. Monitor for adequate clinical response to bupropion when coadministered with CYP2B6 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of ceritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid with strong CYP3A4 inhibitors. If unable to avoid, reduce nilotinib dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciclesonide inhaled",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of ciclesonide inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase certain systemic corticosteroid concentrations. Increased risk for Cushing syndrome and adrenal suppression. Consider alternant corticosteroids, including beclomethasone and prednisolone)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Do not exceed clarithromycin doses >1,000 mg/day in patients taking protease inhibitors. Consider clarithromcycin dose reduction in patients with renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabigatran",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of dabigatran by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Clinical significance dependent on degree of renal impairment. Dabigatran is mainly cleared by glomerular filtration. The prodrug of dabigatran is a substrate of P-gp and concentrations may increase due to inhibition of P-gp by ritonavir. Dabigatran dose may need to be reduced in patients with mild/moderate renal impairment if coadministered with a P-gp inhibitor. Dabigatran is not recommended in patients with severe renal impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased nirmatrelvir/ritonavir or protease inhibitor adverse events with concomitant use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dasatinib",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of dasatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Dose reduction of dasatinib may be necessary if coadministered with strong CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase certain systemic corticosteroid concentrations. Increased risk for Cushing syndrome and adrenal suppression. Consider alternant corticosteroids, including beclomethasone and prednisolone)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Measure serum digoxin concentrations before initiating nirmatrelvir/ritonavir. Decrease digoxin dose by ~30-50% or by modifying dosing frequency and continue monitoring during coadministration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diltiazem",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing diltiazem dose by 50% during coadministration and for 3 more days after the last nirmatrelvir/ritonavir dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxazosin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of doxazosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for increased bradycardia, hypotension, or dizziness. If needed, temporarily pause the antihypertensive drug. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "edoxaban",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of edoxaban by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Coadministration is expected to increase edoxaban concentrations due to P-gp inhibition by ritonavir. Consider temporary edoxaban dose reduction or switching to LWMH. Resume usual edoxaban dose days after last nirmatrelvir/ritonavir dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of erythromycin base by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for increased erythromycin adverse effects, including QTc interval prolongation. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of erythromycin ethylsuccinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for increased erythromycin adverse effects, including QTc interval prolongation. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of erythromycin lactobionate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for increased erythromycin adverse effects, including QTc interval prolongation. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of erythromycin stearate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for increased erythromycin adverse effects, including QTc interval prolongation. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "nirmatrelvir/ritonavir will decrease the level or effect of ethinylestradiol by  increasing metabolism. Modify Therapy/Monitor Closely. Consider using additional nonhormonal contraceptive method for remainder of cycle. Mechanism unknown, but possibly by ritonavir CYP2C9 or CYP1A2 induction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felodipine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing felodipine dose by 50% during coadministration and for 3 more days after the last nirmatrelvir/ritonavir dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Careful monitoring of fentanyl therapeutic and adverse effects (including potentially fatal respiratory depression) recommended when coadministered. Reduce fentanyl dose if necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluticasone furoate",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of fluticasone furoate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase certain systemic corticosteroid concentrations. Increased risk for Cushing syndrome and adrenal suppression. Consider alternant corticosteroids, including beclomethasone and prednisolone)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluticasone inhaled",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of fluticasone inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase certain systemic corticosteroid concentrations. Increased risk for Cushing syndrome and adrenal suppression. Consider alternant corticosteroids, including beclomethasone and prednisolone)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of fosamprenavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased nirmatrelvir/ritonavir or protease inhibitor adverse events with concomitant use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Careful monitoring of hydrocodone therapeutic and adverse effects (including potentially fatal respiratory depression) recommended when coadministered. Reduce hydrocodone dose if necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased nirmatrelvir/ritonavir or protease inhibitor adverse events with concomitant use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "itraconazole",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Limit itraconazole adult dose to 200 mg/day if coadministered with ritonavir."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of ivacaftor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce dosage of ivacaftor, elexacaftor/tezacaftor/ivacaftor, or tezacaftor/ivacaftor  if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Limit ketoconazole adult dose to 200 mg/day if coadministered with ritonavir."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "labetalol",
            "description": {
                "common": "nirmatrelvir/ritonavir will decrease the level or effect of labetalol by  Other (see comment). Use Caution/Monitor. Labetalol undergoes glucuronidation by UGT1A1 and 2B7. Coadministration may decrease labetalol exposure owing to induction of UGT2B7 by ritonavir. Since induction reaches maximal effect after several days and the short duration of nirmatrelvir/ritonavir treatment, no dosage modification is needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of levoketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Limit ketoconazole adult dose to 200 mg/day if coadministered with ritonavir."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lidocaine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of lidocaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution warranted. Monitor lidocaine therapeutic concentrations if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lumateperone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of lumateperone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce lumateperone dose to 10.5 mg/day if coadministered with strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methadone",
            "description": {
                "common": "nirmatrelvir/ritonavir will decrease the level or effect of methadone by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Methadone is metabolized by CYP2B6 and CYP3A4. Ritonavir may decrease AUC and peak plasma concentration by CYP2B6 induction. This may be partially offset by ritonavir inhibiting CYP3A4. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase certain systemic corticosteroid concentrations. Increased risk for Cushing syndrome and adrenal suppression. Consider alternant corticosteroids, including beclomethasone and prednisolone)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirvetuximab soravtansine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of mirvetuximab soravtansine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with strong CYP3A4 inhibitors may increase unconjugated DM4 (a CYP3A4 substrate and the cytotoxic component of the antibody drug conjugate for mirvetuximab soravtansine) exposure, which may increase the risk of adverse reactions. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mometasone inhaled",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of mometasone inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase certain systemic corticosteroid concentrations. Increased risk for Cushing syndrome and adrenal suppression. Consider alternant corticosteroids, including beclomethasone and prednisolone)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased nirmatrelvir/ritonavir or protease inhibitor adverse events with concomitant use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of nevirapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of nicardipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for side effects (eg, hypotension, flushing, edema). May consider temporary nicardipine dose reduction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nifedipine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing nifedipine dose by 50% during coadministration and for 3 more days after the last nirmatrelvir/ritonavir dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxycodone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of oxycodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Careful monitoring of oxycodone therapeutic and adverse effects (including potentially fatal respiratory depression) recommended when coadministered. Reduce oxycodone dose if necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase certain systemic corticosteroid concentrations. Increased risk for Cushing syndrome and adrenal suppression. Consider alternant corticosteroids, including beclomethasone and prednisolone)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce quetiapine dose to one-sixth when coadministered with strong CYP3A4 inhibitors. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "raltegravir",
            "description": {
                "common": "nirmatrelvir/ritonavir will decrease the level or effect of raltegravir by  Other (see comment). Use Caution/Monitor. Raltegravir is an UGT1A1 substrate. Ritonavir induces UGT 1A1."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifabutin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of rifabutin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitored closely for rifabutin adverse effects, including neutropenia and uveitis. Ritonavir prescribing information recommends reducing rifabutin doses by at least 75% to 150 mg every other day, or 3 times weekly, when coadministered with ritonavir. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "riociguat",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of riociguat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Riociguat is metabolized by CYP3A4 and eliminated unchanged in the bile and renally. Consider temporary dose reduction of riociguat and monitor for signs and symptoms of hypotension.  "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosuvastatin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of rosuvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider temporary discontinuation of rosuvastatin during treatment with nirmatrelvir/ritonavir."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased nirmatrelvir/ritonavir or protease inhibitor adverse events with concomitant use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir AF",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of tenofovir AF by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase tenofovir systemic exposures."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased nirmatrelvir/ritonavir or protease inhibitor adverse events with concomitant use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adverse reactions of nausea, dizziness, hypotension, and syncope observed following coadministration of trazodone and strong CYP3A4 inhibitors. Consider lower trazodone dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of triamcinolone acetonide injectable suspension by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase certain systemic corticosteroid concentrations. Increased risk for Cushing syndrome and adrenal suppression. Consider alternant corticosteroids, including beclomethasone and prednisolone)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone inhaled",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of triamcinolone inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may increase certain systemic corticosteroid concentrations. Increased risk for Cushing syndrome and adrenal suppression. Consider alternant corticosteroids, including beclomethasone and prednisolone)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vardenafil",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Limit vardenafil dose to 2.5 mg/72 hr"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "nirmatrelvir/ritonavir increases levels of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for increased bradycardia, hypotension, or dizziness. If needed,  temporarily pause the antihypertensive drug. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vinblastine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may lead to significant hematologic or gastrointestinal side effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vincristine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration may lead to significant hematologic or gastrointestinal side effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voxilaprevir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of voxilaprevir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. INR may increase or decrease. Closely monitor INR if nirmatrelvir/ritonavir is coadministered with warfarin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of zanubrutinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce zanubrutinib (a CYP3A4 substrate) to 80 mg PO BID when coadministered with a moderate CYP3A4 inhibitor. Interrupt dose as recommended for adverse reactions. After discontinuing the CYP3A4 inhibitor, resume previous zanubrutinib dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zidovudine",
            "description": {
                "common": "nirmatrelvir/ritonavir will decrease the level or effect of zidovudine by  unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "emtricitabine",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of emtricitabine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "irbesartan",
            "description": {
                "common": "nirmatrelvir/ritonavir will decrease the level or effect of irbesartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown. Irbesartan metabolized by glucuronidation and oxidation (mainly CYP2C9). Ritonavir is a weak CYP2C9 inducer and could potentially decrease irbesartan exposure. No dosage modification needed since induction reaches maximal effect after several days and the short duration of nirmatrelvir/ritonavir treatment."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "losartan",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown. Losartan is converted to its active metabolite mainly by CYP2C9 in the range of clinical concentrations. In vitro and in vivo data indicate that ritonavir is a weak inducer of CYP2C9. Nirmatrelvir/ritonavir could potentially increase the conversion to the more pharmacologically active metabolite."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "macitentan",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of macitentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Macitentan is metabolized mainly by CYP3A4, but is not a substrate of OATPs. The magnitude of interaction is expected to be low. No dosage adjustment required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "nirmatrelvir/ritonavir, mycophenolate. Other (see comment). Minor/Significance Unknown. \nComment: Mycophenolate mofetil is a prodrug of mycophenolic acid (MPA). MPA undergoes glucuronidation; coadministration of inducers or inhibitors of glucuronidation (eg, ritonavir) could alter mycophenolate levels. ."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of sacubitril/valsartan by  Other (see comment). Minor/Significance Unknown. Valsartan is a substrate of the hepatic uptake transporters OATP1B1 and MRP2.  Ritonavir inhibits these transporters. No dosage modification needed since induction reaches maximal effect after several days and the short duration of nirmatrelvir/ritonavir treatment."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sofosbuvir/velpatasvir",
            "description": {
                "common": "nirmatrelvir/ritonavir will decrease the level or effect of sofosbuvir/velpatasvir by  affecting hepatic enzyme CYP2B6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "valsartan",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of valsartan by  Other (see comment). Minor/Significance Unknown. Valsartan is a substrate of the hepatic uptake transporters OATP1B1 and MRP2.  Ritonavir inhibits these transporters. No dosage modification needed since induction reaches maximal effect after several days and the short duration of nirmatrelvir/ritonavir treatment."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Death or life",
            "percent": "3500"
        },
        {
            "name": "threatening adverse event",
            "percent": null
        },
        {
            "name": "Medical or surgical intervention to prevent death",
            "percent": null
        },
        {
            "name": "life",
            "percent": null
        },
        {
            "name": "threatening event",
            "percent": null
        },
        {
            "name": "hospitalization",
            "percent": null
        },
        {
            "name": "disability",
            "percent": null
        },
        {
            "name": "or congenital anomaly",
            "percent": null
        },
        {
            "name": "Inpatient hospitalization or prolongation of existing hospitalization",
            "percent": null
        },
        {
            "name": "Persistent or significant incapacity or substantial disruption of ability to conduct normal life functions",
            "percent": null
        },
        {
            "name": "or",
            "percent": null
        },
        {
            "name": "Congenital anomaly",
            "percent": null
        },
        {
            "name": "birth defect",
            "percent": null
        },
        {
            "name": "FDA recommends that such reports",
            "percent": null
        },
        {
            "name": "use FDA Form",
            "percent": null
        }
    ]
}